Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Amos Fung"'
Autor:
Bianca J. Lee, Sharmila Mallya, Nuntana Dinglasan, Amos Fung, Tram Nguyen, Lee-or Herzog, Joshua Thao, Edward G. Lorenzana, David Wildes, Mallika Singh, Jacqueline A. M. Smith, David A. Fruman
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (e
Externí odkaz:
https://doaj.org/article/0ce53ca3736040b0b923689cf9147f19
Autor:
Nancy Nguyen, Ze'ev Ronai, Sharmila Mallya, Roberta Buono, J. Scott Lee, Anthony B. Pinkerton, Boyang Li, Amos Fung, David A. Fruman, Michael R. Jackson, Beth Walters, Lee-or Herzog, Robert J. Schneider, Honyin Chiu
Publikováno v:
British Journal of Cancer
British journal of cancer, vol 124, iss 6
British journal of cancer, vol 124, iss 6
Background The BCL2 inhibitor venetoclax has shown efficacy in several hematologic malignancies, with the greatest response rates in indolent blood cancers such as chronic lymphocytic leukaemia. There is a lower response rate to venetoclax monotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3e149b3e92e1cf9b4908b4bc85b95ff
http://europepmc.org/articles/PMC7960756
http://europepmc.org/articles/PMC7960756
Autor:
Mallika Singh, Bianca J. Lee, Joshua Thao, Edward G. Lorenzana, David Wildes, Tram Nguyen, Jacqueline Smith, Amos Fung, Lee-or Herzog, David A. Fruman, Sharmila Mallya, Nuntana Dinglasan
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
The mechanistic target of rapamycin (mTOR) is a kinase whose activity is elevated in hematological malignancies. mTOR-complex-1 (mTORC1) phosphorylates numerous substrates to promote cell proliferation and survival. Eukaryotic initiation factor 4E (e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77ef2bee04da5088b82a5545dba23075
https://doi.org/10.3389/fonc.2021.673213
https://doi.org/10.3389/fonc.2021.673213
Autor:
Jacqueline Smith, Amos Fung, Bianca J. Lee, Ze'ev Ronai, Honyin Chiu, Thanh-Trang Vo, Lee-or Herzog, David A. Fruman, James B. Aggen, Nidhi Tibrewal, David Wildes, Davide Ruggero, Mallika Singh, Sharmila Mallya
Publikováno v:
Molecular Cancer Research. 18:IA17-IA17
mTORC1 signaling is elevated in most lymphoid malignancies and frequently is associated with poor prognosis. Targeting mTORC1 with rapalogs or mTOR kinase inhibitors (TOR-KIs) are two strategies that both have limitations. Rapalogs are weak inducers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e13b2572f81419efb863417a60e5ba8
https://doi.org/10.1158/1557-3125.pi3k-mtor18-ia17
https://doi.org/10.1158/1557-3125.pi3k-mtor18-ia17